Corvus Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Corvus Pharmaceuticals

08/08/2023 22:02

* Corvus Pharmaceuticals Inc  CRVS.OQ  reported a quarterly
adjusted loss of 14 cents​​ per share for the quarter ended in
June. The mean expectation of four analysts for the quarter was
for a loss of 14 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Corvus Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 14 cents​.
    * The mean earnings estimate of analysts had fallen by
about 11.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Corvus Pharmaceuticals Inc shares had fallen by 8.7% this
quarter and gained 145.9% so far this year.
    * The company reported a quarterly loss of $6.5 million.
    * Wall Street's median 12-month price target for Corvus
Pharmaceuticals Inc is $6.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 09:02 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.14          -0.14          Met
 Mar. 31 2023      -0.16          -0.17          Missed
 Dec. 31 2022      -0.23          -0.21          Beat
 Sep. 30 2022      -0.16          -0.32          Missed